Zosano Pharma Corp (ZSAN) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Cash flows from operating activities:
Net loss	-29.9	-33.4	-37.6	-35.4	-29.1	-29.8	-28.4	-14.2
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1.8	1.4	0.7	0.8	2.6	2.5	2.5	3.0
Stock-based compensation	1.9	1.6	1.6	1.2	0.7	1.2	0.7	0.2
Change in operating lease right-of-use assets	1.2	1.0	0.8
Accretion of asset retirement obligation	0.1	0.1
Effective interest on financing obligations	0.4	0.7	0.9	0.3	0.1
Capitalized effective interest	-0.4	-0.4	-0.6
Loss on impairment of long-lived assets							0.1	0.2
Change in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets	-0.1	0.0	0.1	0.0	0.0	0.0	-0.2	0.2
Accounts payable	0.6	-1.5	1.8	0.1	0.0	0.2	0.7	-2.6
Accrued compensation and other accrued liabilities	-0.1	0.0	-1.3	1.7	-0.2	0.1	-0.1
Operating lease liabilities	-1.4	-1.2	-1.0
Net cash used in operating activities	-27.6	-31.7	-34.8	-29.1	-26.8

Cash flows from investing activities:
Purchases of property and equipment	-5.4	-8.5	-11.8	-5.5	-1.2		-0.4	-1.2
Net cash used in investing activities	-5.4	-8.5	2.2	-19.2	-1.2

Cash flows from financing activities:
Proceeds from public offering of securities					26.6		47.1
Principal payments on financing obligations
Net cash provided by financing activities	8.8	69.2	29.8	45.8	25.0

Cash and cash equivalents
Restricted cash

Supplemental cash flow information:
Cash paid for interest	0.6	1.0	0.8	0.9	0.9	1.2	3.6	0.2
Non-cash investing and financing activities:
Acquisition of property and equipment under accounts payable and other accrued liabilities	1.1	3.1	4.4	3.4	0.1	0.1
Accrued offering costs	0.1		0.2